#### SUPPORTING INFORMATION

## A Redox Economical Synthesis of Bioactive 6,12-Guaianolides

Bo Wen, Joseph K. Hexum, John C. Widen, Daniel A. Harki\* and Kay M. Brummond\*

Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260 Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55414

TABLE OF CONTENTS FOR SUPPORTING INFORMATION	PAGE
I. SUPPLEMENTAL FIGURE 1	S2
II. SUPPLEMENTAL FIGURE 2	S3
III. SUPPLEMENTAL FIGURE 3	S4
IV. CELL CULTURE	S4
V. PREPARATION OF STOCK SOLUTIONS FOR COMPOUNDS	S4
VI. CELL CULTURE CYTOTOXICITY ASSAYS	S5
VII. NF-KB REPORTER ASSAYS	S5



**I. Supplemental Figure 1.** Representative IC<sub>50</sub> curves for **22a** (closed diamonds), **22b** (open triangles), parthenolide (PTL; closed squares), doxorubicin (Dox.; open diamonds), and gemcitabine (Gem.; closed triangles) against (A) DU-145, (B) HeLa, and (C) HL-60 cells. Viability was determined via Alamar Blue assay. Error bars represent the S.D. of triplicate data.  $IC_{50}$  values are in micromolar ( $\mu$ M) units.



**II.** Supplemental Figure 2. Representative IC<sub>50</sub> curves for 22a (closed diamonds), 22b (open triangles), parthenolide (PTL; closed squares), doxorubicin (Dox.; open diamonds), and gemcitabine (Gem.; closed triangles) against (A) U-87 MG, (B) NCI/ADR-RES, and (C) Vero cells. Viability was determined by Alamar Blue assay. Error bars represent the S.D. of triplicate data. IC<sub>50</sub> values are in micromolar ( $\mu$ M) units.



**III. Supplemental Figure 3.** Representative cytotoxicity data for **22a**, **22b**, and parthenolide (PTL) against A549/NF- $\kappa$ B-luc cells. Compounds **22a** and **22b** were tested at 20, 10, and 1  $\mu$ M concentrations and PTL was tested at 10 and 1  $\mu$ M concentrations. Cell viability was determined using the Alamar Blue assay. For each compound, < 10% cell death was observed at each tested concentration.

# IV. Cell Culture

All cell lines were maintained in a humidified 5% CO<sub>2</sub> environment at 37 °C. HL-60 cells (ATCC, CCL-240) were cultured in IMDM media (Cellgro) supplemented with 20% fetal bovine serum (FBS, Gibco), penicillin (100 I.U./mL), and streptomycin (100  $\mu$ g/mL, ATCC) at a density of 1 × 10<sup>5</sup> – 1 × 10<sup>6</sup> cells/mL. HeLa cells (ATCC, CCL-2) were cultured in MEM media (Cellgro) supplemented with 10% FBS, penicillin (100 I.U./mL), and streptomycin (100  $\mu$ g/mL ATCC). U-87 MG cells (ATCC, HTB-14) were cultured in MEM media (Cellgro) supplemented with 10% FBS, penicillin (100 I.U./mL), and streptomycin (100  $\mu$ g/mL ATCC). NCI/ADR-RES cells were cultured in RPMI-1640 media (Cellgro) supplemented with 10% FBS, penicillin (100  $\mu$ g/mL ATCC). DU-145 cells and Vero cells were cultured as described previously.<sup>1</sup>

# V. Preparation of Stock Solutions for Compounds

Stock solutions for compounds were prepared in DMSO and stored at -20° C when not in use. Compound purities were assessed frequently by analytical reverse-phase HPLC analysis and fresh solutions were prepared as needed. All tested compounds were > 95% pure. Doxorubicin hydrochloride was purchased from Fisher Scientific (Cat. #BP251610), gemcitabine hydrochloride was purchased from USP (Cat. #1288463), and parthenolide was purchased from Enzo Life Sciences (Cat. #BML-T113-0250). Parthenolide was purified by SiO<sub>2</sub> chromatography (0-40% ethyl acetate in hexanes) prior to biological testing.

<sup>&</sup>lt;sup>1</sup> Hexum, J. K.; Tello-Aburto, R.; Struntz, N. B.; Harned, A. M.; Harki, D. A. ACS Med. Chem. Lett. **2012**, 3, 459-464

#### VI. Cell Culture Cytotoxicity Assays

HL-60 cells were seeded at a density of 10,000 cells/well in cell culture media (50  $\mu$ L) in standard 96-well plates (Costar) 24 h prior to treatment. HeLa, U-87 MG, NCI/ADR-RES, Vero, and DU-145 cells were seeded at a density of 5,000 cells/well in cell culture media (50  $\mu$ L) in standard 96-well plates (Costar). In vitro Alamar Blue (Invitrogen) cytotoxicity assays were performed as described previously.<sup>1</sup> The DMSO concentration in each assay plate well was kept constant at 0.5%. Due to overlapping absorbance of doxorubicin (580 nm) with Alamar Blue at concentrations greater than 500  $\mu$ M, absorbance values were obtained before the addition of Alamar Blue. The resulting values were used to calculate the IC<sub>50</sub>.

## VII. NF-κB Reporter Assays

This assay was performed as described previously.<sup>1</sup>